Oct 16, 2018
ANI Announces Launch of Authorized Generic of Brethine®
Oct 04, 2018
ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets
Sep 27, 2018
ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Aug 08, 2018
ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference
Aug 07, 2018
ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance
Aug 06, 2018
ANI Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference
Aug 01, 2018
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results
Jun 27, 2018
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
Jun 05, 2018
ANI Shareholders Elect Three New Members to the Board of Directors
May 08, 2018
ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
May 07, 2018
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
May 01, 2018
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
Apr 27, 2018
Amneal And Impax Receive FTC Clearance For Business Combination
Apr 27, 2018
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax
Apr 18, 2018
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
Apr 04, 2018
ANI Acquires 23 ANDAs from IDT Australia, Ltd.
Mar 02, 2018
ANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors Conference
Feb 27, 2018
ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance
Feb 20, 2018
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance
Dec 29, 2017
ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million